Editorial: Immune-related adverse Events (irAEs) of biopharmaceuticals

Alexander Batista-Duharte; Salvador F Aliño

doi:10.3389/falgy.2023.1214914

Editorial: Immune-related adverse Events (irAEs) of biopharmaceuticals

Front Allergy. 2023 May 24:4:1214914. doi: 10.3389/falgy.2023.1214914. eCollection 2023.

Authors

Alexander Batista-Duharte¹, Salvador F Aliño^{2

3}

Affiliations

¹ Immunology and Allergy Group (GC01), Maimonides Biomedical Research Institute of Cordoba (IMIBIC), University of Cordoba, Reina Sofia University Hospital, Cordoba, Spain.
² Farmacogenetics and Gene Therapy Group, Instituto de Investigación Sanitaria La Fe, Valencia, Spain.
³ Gene Therapy and Pharmacogenomics Group, Department of Pharmacology, Faculty of Medicine, University of Valencia, Valencia, Spain.

No abstract available

Keywords: antibodies; cell-based therapy; delivery systems; immune-related adverse events (irAEs); nucleic acids; polysaccharides; proteins; vaccines.

Publication types

Editorial

Grants and funding

AB-D has received funding from the European Union's Horizon 2020 research and innovation program under the Marie Skłodowska-Curie “grant agreement No 847468”. Currently, AB-D is working with a Miguel Servet contract (CP22/00111) from Instituto Salud Carlos III, Spain Government and European Union.